Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.03), $0.79 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $99.4 million versus the consensus estimate of $77.04 million.

“We continue to have strong Crysvita and Dojolvi launches and execute on our development priorities across our pipeline,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “In 2021, we will have ongoing pivotal trials for three gene therapies, one pivotal monoclonal antibody study for osteogenesis imperfecta, our first mRNA program for GSDIII, and an antisense oligonucleotide for Angelman with our partner GeneTx. These six clinical programs along with our commercial and early-stage programs make ours one of the most diversified pipelines in rare disease.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.